LONDON, Aug. 18, 2022 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that the TSX Venture Exchange (the “TSXV”) has accepted the Company’s application for its normal course issuer bid (the “NCIB”) for up to five million…
